Source Paper
Source Paper
E Berry-Kravis, D Hessl, S Coffey, C Hervey, A Schneider et al.
Journal of Medical Genetics • 2009
Objective: A pilot open label, single dose trial of fenobam, an mGluR5 antagonist, was conducted to provide an initial evaluation of safety and pharmacokinetics in adult males and females with fragile X syndrome (FXS). Methods: Twelve subjects, recruited from two fragile X clinics, received a single oral dose of 50–150 mg of fenobam. Blood for pharmacokinetic testing, vital signs and side effect screening was obtained at baseline and numerous time points for 6 h after dosing. Outcome measures included prepulse inhibition (PPI) and a continuous performance test (CPT) obtained before and after dosing to explore the effects of fenobam on core phenotypic measures of sensory gating, attention and inhibition. Results: There were no significant adverse reactions to fenobam administration. Pharmacokinetic analysis showed that fenobam concentrations were dose dependent but variable, with mean (SEM) peak values of 39.7 (18.4) ng/ml at 180 min after the 150 mg dose. PPI met a response criterion of an improvement of at least 20% over baseline in 6 of 12 individuals (4/6 males and 2/6 females). The CPT did not display improvement with treatment due to ceiling effects. Conclusions: Clinically significant adverse effects were not identified in this study of single dose fenobam across the range of dosages utilised. The positive effects seen in animal models of FXS treated with fenobam or other mGluR5 antagonists, the apparent lack of clinically significant adverse effects, and the potential beneficial clinical effects seen in this pilot trial support further study of the compound in adults with FXS.
Objective: Assessment of sensorimotor gating and inhibitory control using acoustic startle stimuli with prepulses at 120 ms and 240 ms intervals while recording electromyographic responses
Gather these items before starting the experiment. Check off items as you prepare.
Not specified • Not specified • Not specified • N/A
Not specified • Not specified • Not specified • N/A
Not specified • Not specified • Not specified • N/A
Not specified • Not specified • Not specified • N/A
Not specified • Not specified • Not specified • N/A
Not specified • Not specified • Not specified • N/A
Not specified • N/A
1 item available from ConductScience
Estimated: $7,990.00
As an Amazon Associate, we earn from qualifying purchases. Product links help support this free resource.
Subjects undergo comprehensive medical evaluation including medical history, physical exam, vital signs, laboratory testing (routine chemistries, blood counts, thyroid functions), electrocardiogram (ECG), and pregnancy test for females.
Note: Baseline CPT and prepulse inhibition (PPI) outcome measures obtained at this visit
“At the screening visit medical history, exam, vital signs, laboratory testing including routine chemistries, blood counts, thyroid functions, electrocardiogram (ECG), and a pregnancy test (females) were evaluated, and baseline CPT (Carolina Project Fragile X continuous performance test) and prepulse inhibition (PPI) outcome measures were obtained.”
Baseline prepulse inhibition test performed at screening visit to establish baseline sensorimotor gating measurements
Note: Baseline measurements used for comparison with post-treatment PPI
“baseline CPT (Carolina Project Fragile X continuous performance test) and prepulse inhibition (PPI) outcome measures were obtained”
Carolina Fragile X Project Continuous Performance Test administered at screening visit to assess baseline attention, impulsivity, and inhibition
Note: Baseline measurements used for comparison with post-treatment CPT
“baseline CPT (Carolina Project Fragile X continuous performance test) and prepulse inhibition (PPI) outcome measures were obtained”
14-28 days after screening visit, intravenous catheter inserted for blood drawing. Subject receives study medication orally. Dose depends on subject gender and enrollment order: first subject of each gender receives 50 mg fenobam, second receives 100 mg, all subsequent subjects receive 150 mg.
Note: Conference calls held after each subject dosed to confirm absence of adverse events and justify dose escalation or maintenance
“At the treatment visit, 14–28 days after screening, an IV was inserted for blood drawing and the subject received the study medication orally. The first subject for each gender was dosed with 50 mg fenobam, the second with 100 mg, and all subsequent subjects with 150 mg.”
Blood samples collected for pharmacokinetic testing at multiple timepoints: 0, 15, 30, 45, 60, 120, 180, 240, 300, and 360 minutes after dosing
Note: Blood pressure and heart rate also monitored at these timepoints
“Blood for pharmacokinetic testing, blood pressure, heart rate and side effect screening was obtained at 0, 15, 30, 45, 60, 120, 180, 240, 300, and 360 min after dosing.”
Structured side effects screening protocol involving questioning of subject and family members about specific symptoms relevant to fenobam effects (aggression, fatigue, hyperactivity, anxiety and fidgetiness, increase in self stimulation, odd behaviour, inappropriate laughter, dizziness, vertigo, nausea, paraesthesia, and headache), plus direct observation by physician and family for these symptoms and other behavioral changes
Note: Conducted at 0, 15, 30, 45, 60, 120, 180, 240, 300, and 360 minutes after dosing
“Our side effects screening protocol involved asking both the subject and family members if the subject was having any of a structured list of symptoms relevant to potential effects of fenobam (aggression, fatigue, hyperactivity, anxiety and fidgetiness, increase in self stimulation, odd behaviour, inappropriate laughter, dizziness, vertigo, nausea, paraesthesia, and headache), and direct observation by the physician and family for the above symptoms and other behavioural changes.”
Prepulse inhibition test performed after 60 minute blood sampling timepoint to assess medication effects on sensorimotor gating
Note: Performed after 60 min blood sampling, before CPT
“Post-treatment PPI was performed after the 60 min blood sampling, followed by CPT.”
Deliver 10 trials of startle stimulus alone. Startle stimuli are 50 ms 105 dB SPL white noise pulses. Participant watches silent movie during trials.
Note: Part of 30 total trial protocol. Electromyographic responses recorded between 20 ms and 200 ms post startle probe onset
“Startle stimuli (SS) were 50 ms 105 db SPL white noise pulses and acoustic prepulses (PP) are 25 ms 75 db SPL 1 kHz tones. These trials are delivered while participants watch a silent movie to maintain compliance and interest in the procedure. resulting in a protocol with 30 total trials (10 with SS alone, 10 with 120 ms prepulse and 10 with 240 ms prepulse)”
Deliver 10 trials with 120 ms prepulse interval. Acoustic prepulses are 25 ms 75 dB SPL 1 kHz tones, followed 120 ms later by startle stimulus (50 ms 105 dB SPL white noise pulse). Participant watches silent movie during trials.
Note: 120 ms prepulse interval has excellent test-retest reliability (intraclass correlation 0.85 for FXS, 0.88 for controls). Most reliable trial latency for determining responders.
“10 with 120 ms prepulse and 10 with 240 ms prepulse. PPI at 120 ms has excellent test-retest reliability with intraclass correlations of 0.85 for FXS and 0.88 for controls”
Deliver 10 trials with 240 ms prepulse interval. Acoustic prepulses are 25 ms 75 dB SPL 1 kHz tones, followed 240 ms later by startle stimulus (50 ms 105 dB SPL white noise pulse). Participant watches silent movie during trials.
Note: 240 ms prepulse interval has good to excellent test-retest reliability. 60 ms interval was eliminated due to inadequate reliability.
“Test-retest studies have demonstrated good to excellent reliability for PPI at 120 ms and 240 ms, but inadequate reliability for PPI at 60 ms. Therefore, for the current study, we eliminated the 60 ms trial type and added two trials per type, resulting in a protocol with 30 total trials”
Digitized orbicularis oculi electromyographic peak magnitudes recorded between 20 ms and 200 ms post startle probe onset. Peak magnitudes averaged across trials within each trial type (SS alone, 120 ms prepulse, 240 ms prepulse).
Note: Three separate averages calculated: one for SS alone trials, one for 120 ms prepulse trials, one for 240 ms prepulse trials
“Digitised obicularis oculi electromyographic peak magnitudes recorded between 20 ms and 200 ms post startle probe onset were averaged across trials within each type.”
Carolina Fragile X Project Continuous Performance Test administered after post-treatment PPI to assess effects on attention, impulsivity, and inhibition. Number of correct hits on target stimuli, omissions (lack of reaction to target), and commissions (reaction to non-target) are tabulated.
Note: Commission score is main focus of analysis as more reliable marker for abnormal performance
“Post-treatment PPI was performed after the 60 min blood sampling, followed by CPT. the number of correct hits on a target stimuli, omissions involving lack of reaction to a target (attention deficit), and commissions involving reacting to a non-target (impulsivity, poor inhibitory control) were tabulated.”
Fenobam concentrations from plasma samples measured using MS-MS based assays validated for human application with positive ion liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS). Plasma samples over 24 hours obtained from three healthy adult male volunteers for comparison.
Note: Assays are validated for human application
“Fenobam concentrations from plasma samples were measured with MS-MS based assays validated for human application, using positive ion liquid chromatography/mass spectrometry/mass spectrometry (LC/MS/MS). For comparison, plasma samples over 24 h were obtained from three healthy adult male volunteers.”
Subjects with fragile X syndrome (FXS) recruited from fragile X clinics at Rush University Medical Center (RUMC) and MIND Institute at University of California at Davis Medical Center (UCDMC). Subjects were verbal and sufficiently high functioning to report side effects.
Evidence-Based
21 quotes from paper
No institutional citation data available yet.